N

NewAmsterdam Pharma

Biopharma developing LDL-C lowering CETP therapies

Vice President - Commercial Counsel

Full-Time
No salary listed
Expert
JD
Remote in USA
HybridRemote within the United States, with in-person attendance at the Philadelphia-area office based on business needs.

About the job

Requirements
  • A J.D. from an accredited law school and admission in good standing to at least one U.S. state bar.
  • At least 10 years of relevant legal experience advising pharmaceutical, biotechnology, or life sciences companies, in-house and/or at a law firm.
  • Demonstrated expertise in market access, trade and distribution, and patient support programs, including healthcare fraud and abuse, government program, privacy, and commercialization considerations.
  • Experience supporting a pharmaceutical or biotechnology product launch and advising on complex commercial arrangements with sophisticated healthcare and life sciences counterparties.
  • Familiarity with HCP engagements, sales, marketing and other commercial programs, and promotional and non-promotional communications review.
  • Strong legal and business judgment, communication skills, relationship-building ability, adaptability, and comfort operating with ambiguity and competing priorities.
  • A practical, accountable, hands-on approach with the ability to translate complex requirements into clear advice and actionable solutions.
  • Ability to attend the NAP office in the Philadelphia area in person based on business needs and work requirements.
Responsibilities
  • Advise on payer and PBM engagement, formulary access, contracting, pricing, reimbursement, rebate arrangements, government program considerations, and other market access initiatives.
  • Counsel on channel strategy, wholesaler and specialty pharmacy relationships, distribution arrangements, service-fee structures, data arrangements, inventory and product-flow issues, and related contracts.
  • Advise on benefits verification, prior authorization support, copay assistance, patient assistance programs, adherence and education services, privacy, fraud and abuse, and hub and vendor relationships.
  • Serve as a trusted legal advisor to the commercial organization before and after launch, translating legal and regulatory requirements into clear, practical, business-oriented advice.
  • Partner with business leaders to understand objectives, anticipate issues, assess risk in context, and develop creative, compliant paths forward.
  • Support launch strategies, capabilities, policies, business processes, and cross-functional decision-making across Legal, Compliance, Commercial, Medical Affairs, Finance, Market Access, Patient Services, and other functions.
  • Take ownership of matters from issue identification through resolution while working hands-on with business partners in a fast-moving environment.
  • Draft, review, and negotiate agreements supporting launch and commercialization.
  • Develop scalable templates, playbooks, processes, policies, training, and commercial legal capabilities as the organization grows.
  • Provide or coordinate legal guidance on advisory boards, speaker programs, consulting engagements, sponsorships, congress activities, exhibits, business rationale, fair market value, contracting, and related compliance considerations.
  • Support review of promotional, disease awareness, payer, patient, medical, scientific education, and other external-facing materials, providing practical guidance on FDA promotional requirements and related standards.
  • Seek to understand business objectives, commercial context, patient needs, and industry realities before developing legal solutions.
  • Help leaders distinguish theoretical risk from meaningful risk, communicate clearly, and make informed decisions.
  • Build strong relationships across Commercial, Medical Affairs, Finance, Compliance, and other functions.
  • Help build commercial capabilities and execute the company's first commercial product launch.
Desired Qualifications
  • Significant experience and expertise in one or more of HCP engagements, sales, marketing and other commercial programs, and promotional and non-promotional communications review.
  • Deeper experience in HCP engagements, sales, marketing and other commercial programs, or materials review.

About the company

NewAmsterdam Pharma develops oral therapies for cardiometabolic diseases and runs late-stage clinical programs around obicetrapib, a CETP inhibitor aimed at lowering LDL-cholesterol in high-risk cardiovascular disease patients. Its pipeline includes a fixed-dose combo of obicetrapib and ezetimibe in Phase 2 (ROSE2) and three Phase 3 trials (BROADWAY, BROOKLYN, and PREVAIL) to evaluate obicetrapib in HeFH, ASCVD, and as a cardiovascular outcomes trial. Founded in 2019 and based in Naarden, the Netherlands, the company focuses on transforming lipid management and cardiovascular risk reduction through targeted CETP inhibition.

Company Size

51-200

Company Stage

IPO

Headquarters

Naarden, Netherlands

Founded

2019

Get referred to NewAmsterdam Pharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EMA, UK, and Swiss decisions expected in 2H2026 can unlock Germany and UK launches.
  • June 2026 cash of $678.3 million funds PREVAIL, RUBENS, and commercialization through 2027.
  • BROADWAY and BROOKLYN showed LDL-C lowering with placebo-like tolerability, supporting physician adoption.

What critics are saying

  • PREVAIL interim data in 1Q2027 decides the entire platform; failure crushes NewAmsterdam.
  • Merck's July 2026 oral PCSK9 approval steals cardiology mindshare before Menarini launches.
  • COO Douglas Kling resigned effective August 14, 2026, signaling execution strain before launches.

What makes NewAmsterdam Pharma unique

  • Obicetrapib is the only late-stage oral CETP inhibitor; Europe approved it in July 2026.
  • NewAmsterdam pairs monotherapy and ezetimibe FDC across HeFH, ASCVD, and PREVAIL programs.
  • Menarini commercialization in Europe gives NewAmsterdam royalties and milestones without building a salesforce.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -1%

2 year growth

↑ 0%
PR Newswire
Sep 21st, 2026
European Commission approves Menarini and NewAmsterdam's obicetrapib for cholesterol treatment

The European Commission has granted marketing authorisation for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination), marking the first global regulatory approval of obicetrapib. The approval, announced by NewAmsterdam Pharma and Menarini Group, covers treatment for patients with primary hypercholesterolaemia and mixed dyslipidaemia. The authorisation is supported by Phase 3 clinical trials demonstrating LDL cholesterol reductions of up to 40% with obicetrapib monotherapy and approximately 50% when combined with ezetimibe. The treatments showed a tolerability profile comparable to placebo. Menarini holds exclusive commercialisation rights in Europe. NewAmsterdam is entitled to tiered double-digit percentage royalties on net sales and up to €833 million in potential milestone payments. The companies continue advancing obicetrapib's clinical development through multiple ongoing Phase 3 trials, including the PREVAIL cardiovascular outcomes study.

GlobeNewswire
Sep 2nd, 2026
NewAmsterdam Pharma to participate at upcoming investor conferences in September.

NewAmsterdam Pharma to participate at upcoming investor conferences in September. NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: * Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 3:45 p.m. ET on Wednesday, September 9. * Cantor Global Healthcare Conference 2026 in New York, NY on Thursday, September 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:45 p.m. ET on Thursday, September 10. Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company's website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]

NewAmsterdam Pharma
Aug 26th, 2026
NewAmsterdam Pharma announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026.

NewAmsterdam Pharma announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 - 31, 2026 in Munich, Germany. Presentation details are as follows: Title: Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials Session Title: Novel Lipid Lowering Therapies for Residual Risk Session Number: 3579 Moderated Poster Presentation Date and Time: Friday, August 28, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenters: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials Session Title: Lipid Lowering and Cardiovascular Outcomes Session Number: 3582 Moderated Poster Presentation Date and Time: Sunday, August 30, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenter: Mathijs A.C. de Kleer Title: Extreme HDL-C Associated Increased Mortality is Explained by Confounding Due to Progressively Increasing Alcohol-Induced Multisystem Morbidity Session Title: Lipids and Myocardial Infarction Session Number: 3102 Oral Presentation Date and Time: Monday, August 31, 2026 at 12:30-12:40 CET Location: Science Box 5, Research Gateway Hall A1 Presenter: Brian A. Ference, M.D., MPhil, FACC, FESC About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]

Associated Press
Aug 5th, 2026
NewAmsterdam Pharma secures positive CHMP opinion for obicetrapib with $678M cash on hand

NewAmsterdam Pharma reported second quarter 2026 financial results and announced positive regulatory progress for obicetrapib, its cholesterol-lowering drug candidate. The European Medicines Agency's CHMP has recommended marketing authorisation for obicetrapib as both a monotherapy and in combination with ezetimibe for treating hypercholesterolemia and mixed dyslipidemia. A final European Commission decision is expected later this year. The company holds $678.3 million in cash, cash equivalents and marketable securities as of 30 June 2026, down from $728.9 million at year-end 2025. Second quarter net loss was $64.1 million compared to $17.4 million in the same period last year. NewAmsterdam plans an interim analysis of its PREVAIL cardiovascular outcomes trial in fourth quarter 2026, with results expected in first quarter 2027. Topline data from the RUBENS Phase 3 trial is anticipated by year-end 2026.

NewAmsterdam Pharma
Aug 5th, 2026
NewAmsterdam Pharma to host Investor Day on August 5, 2026.

NewAmsterdam Pharma to host Investor Day on August 5, 2026. NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City. Please join members of its management team, including: Michael Davidson, M.D., Chief Executive Officer; John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer; BJ Jones, Chief Commercial Officer; Ian Somaiya, Chief Financial Officer; and Matthew Philippe, Executive Vice President and Head of Investor Relations. A live webcast of the Investor Day event will be available, and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]